Developments FDA accepts Revelation’s IND for Gemini in CKD Revelation Biosciences (NASDAQ:REVB) announced that the FDA has accepted its investigational new drug (IND) application for Gemini in chronic kidney disease (CKD). The company notes that the milestone enables the launch... December 2, 2024